SANTA ANA, Calif., Aug. 18 /PRNewswire-FirstCall/ -- Advanced Medical Optics, Inc. (AMO) today announced that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission (SEC), which automatically became effective upon filing. The registration statement relates to the resale by holders of AMO’s 3.25% Convertible Senior Subordinated Notes due 2026, and the shares of AMO’s common stock issuable upon conversion of the notes. AMO’s initial issuance of the notes, in an aggregate principal amount of $500 million, was completed on June 13, 2006. A copy of the prospectus may be obtained from AMO at 1700 E. St. Andrew Place, Santa Ana, California 92705, Attention: Investor Relations.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO )
The registration statement was filed on behalf of the selling securityholders, and AMO will not receive any proceeds from the resale of the Notes or the underlying common stock.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Advanced Medical Optics (AMO)
AMO is a global medical device leader focused on the discovery and delivery of innovative vision technologies that optimize the quality of life for people of all ages. Products in the cataract/implant line include intraocular lenses, phacoemulsification systems, viscoelastics, and related products used in cataract and refractive lenticular surgery. Products in the laser vision correction line include laser systems, wavefront diagnostic systems, microkeratomes and related products used in corneal refractive surgery. AMO owns or has the rights to such ophthalmic surgical product brands as ReZoom(TM), Clariflex(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM) intraocular lenses, STAR S4 IR(TM) laser vision correction system, WaveScan Wavefront(R) System, CustomVue(TM) procedure, Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with WhiteStar(R) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contact lens care line include disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(TM) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO is based in Santa Ana, California, and employs approximately 3,600 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company’s Web site at www.amo-inc.com.
Investor Contact: Sheree Aronson (714) 247-8290 sheree.aronson@amo-inc.com Media Contact: Steve Chesterman (714) 247-8711 steve.chesterman@amo-inc.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAdvanced Medical Optics, Inc.
CONTACT: Investors, Sheree Aronson, +1-714-247-8290,sheree.aronson@amo-inc.com, or Media, Steve Chesterman, +1-714-247-8711,steve.chesterman@amo-inc.com, both of Advanced Medical Optics, Inc.
Web site: http://www.amo-inc.com/
